Company Overview
Profit after Tax
N/A
Cr
Growth:
N/A
Industry P/S: N/A
Fundamentals
| Sales (Cr) |
₹ N/A |
| Growth |
N/A |
| EBITDA |
N/A |
| P/S |
N/A |
| Dividend |
N/A |
| P/E |
N/A |
| Book Value |
₹ N/A |
| PEG Ratio |
N/A |
| ROE |
N/A |
| P/B |
N/A |
Shareholding Pattern
Increase
Decrease
No change
Dabur Pharma, a leading company for cancer research and oncology drugs, was renamed Fresenius Kabi Oncology after its acquisition by Fresenius Kabi, the leader in infusion therapy and clinical nutrition in Europe, Latin America, Asia Pacific as well as in the US, where it is a leading supplier of IV generic drugs.
